SCHEMBL24374522

SCHEMBL24374522

Cc1ccccc1OCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccc(OC(=O)N2CCC(C(N)=O)CC2)cc1)C(=O)OC(C)OC(=O)C(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 2/20 0.40
ITGA4 P13612 2/20 0.40
UBE2N P61088 1/20 0.40
CASP3 P42574 4/20 0.38
CASP1 P29466 3/20 0.38
CASP7 P55210 3/20 0.38
CASP6 P55212 3/20 0.38
CASP8 Q14790 3/20 0.38
STAT3 P40763 1/20 0.38
YAP1 P46937 3/20 0.37
CACNA1B Q00975 1/20 0.37
PTPN1 P18031 2/20 0.37
PSMB11 A5LHX3 3/20 0.37
PSMA7 O14818 3/20 0.37
PSMB1 P20618 3/20 0.37
PSMA1 P25786 3/20 0.37
PSMA2 P25787 3/20 0.37
PSMA3 P25788 3/20 0.37
PSMA4 P25789 3/20 0.37
PSMB8 P28062 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27217471 1.00 ITGB1 (0.40) ITGB1ITGA4UBE2NCASP3CASP1
SCHEMBL27217462 1.00 ITGB1 (0.40) ITGB1ITGA4UBE2NCASP3CASP1
SCHEMBL27217454 0.95 ITGB1 (0.39) ITGB1ITGA4UBE2NCASP3CASP1
SCHEMBL27217459 0.95 ITGB1 (0.39) ITGB1ITGA4UBE2NCASP3CASP1
SCHEMBL24374731 0.95 ITGB1 (0.39) ITGB1ITGA4UBE2NCASP3CASP1
SCHEMBL24374707 0.95 ITGB1 (0.39) ITGB1ITGA4UBE2NCASP3CASP1
SCHEMBL24374510 0.95 ITGB1 (0.39) ITGB1ITGA4UBE2NCASP3CASP1
SCHEMBL24374728 0.94 ITGB1 (0.38) ITGB1ITGA4UBE2NCASP3CASP1
SCHEMBL22556028 0.94 ITGB1 (0.38) ITGB1ITGA4UBE2NCASP3CASP1
SCHEMBL22556032 0.94 ITGB1 (0.38) ITGB1ITGA4UBE2NCASP3CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158375-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS Azura Ophthalmics Ltd. (IL) 2024-05-16 US disclosed
EP-4232458-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS AZURA OPHTHALMICS LTD (IL) 2023-08-30 EP disclosed
WO-2022084747-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS Azura Ophthalmics Ltd. (IL) 2022-04-28 WO disclosed
WO-2022084747-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS Azura Ophthalmics Ltd. (IL) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158375-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS MPO, MUC1, CRYAB ITGB1 1385/4885ITGA4 1271/4885UBE2N 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.